Is pomalidomide available in capsule form?

The standard dosage form of Pomalidomide is capsule form, which is clearly documented in the global package insert of its original drug POMALYST. The setting of the capsule dosage form not only facilitates oral administration, but also helps control the release rate of the drug in the gastrointestinal tract, improve bioavailability, and ensure that patients can stably obtain the expected drug effect concentration. Among the pomalidomide preparations approved by the US FDA and European EMA for the treatment of multiple myeloma (MM), the main specifications include 1 mg, 2 mg, 3 mg and 4 mg, all of which are oral hard capsules. Patients need to take the prescribed dose every day. It is usually recommended to swallow the medicine on an empty stomach or after meals with enough water to avoid breaking or chewing it.

The advantage of capsule dosage form is that it can achieve precise dose control, especially for immunomodulatory drugs. Slightly exceeding the dose may lead to overactive immune system, inflammation, bone marrow suppression and other serious adverse reactions. Therefore, the clinical use of pomalidomide usually requires individualized dosage adjustment according to body weight, liver and kidney function status, and strictly follows a 28-day cycle of dosage regimen, in which days 1 to 21 are taken and days 22 to 28 are drug withdrawal periods to reduce the accumulation of toxicity.

In addition, the capsule dosage form also facilitates unified global standard management. Pomalidomide is a drug with a high risk of teratogenicity and has a clear label for contraindication during pregnancy. Its capsule packaging must not only prevent children from accidentally taking it, but also must be distributed by a registered pharmacy or hospital. Some countries have implemented the Risk Evaluation and Mitigation Strategy (REMS) program, which requires patients to pass a pregnancy test and receive relevant risk education before they can receive medicines.

In general, as an oral immunomodulator, the capsule dosage form of pomalidomide is designed to meet the clinical needs of long-term, chronic disease treatment, while ensuring drug stability, safety and patient compliance.

Reference materials:https://en.wikipedia.org/wiki/Pomalidomide